Straightforward Selection of Broadly Neutralizing Single-Domain
暂无分享,去创建一个
Patrick Chames | Daniel Baty | Francis Barin | Pereira Ramos | Julie Matz | Pascal Kessler | Jérôme Bouchet | Olivier Combes | Oscar Henrique | Loïc Martin | Serge Benichou | J. Bouchet | P. Kessler | P. Chames | D. Baty | F. Barin | O. Combes | J. Matz | Loïc Martin | S. Bénichou | Oscar Henrique | P. Ramos
[1] A. Álvarez,et al. Broadly neutralizing antibodies and their significance for HIV-1 vaccines. , 2010, Current HIV research.
[2] J. Ulmer,et al. A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide. , 2008, Virology.
[3] Ron Diskin,et al. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity , 2010, Nature Structural &Molecular Biology.
[4] R. Weiss,et al. Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120 , 2008, Journal of Virology.
[5] L. Wyns,et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[6] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[7] G Vassart,et al. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. , 1996, Biochemistry.
[8] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[9] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.
[10] F. Stricher,et al. A high-throughput fluorescence polarization assay specific to the CD4 binding site of HIV-1 glycoproteins based on a fluorescein-labelled CD4 mimic. , 2005, The Biochemical journal.
[11] D. Montefiori,et al. Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. , 2010, The Journal of general virology.
[12] R. Weiss,et al. Generation of a Family-specific Phage Library of Llama Single Chain Antibody Fragments That Neutralize HIV-1* , 2010, The Journal of Biological Chemistry.
[13] F. Roquet,et al. Llama single‐domain antibodies directed against nonconventional epitopes of tumor‐associated carcinoembryonic antigen absent from nonspecific cross‐reacting antigen , 2009, The FEBS journal.
[14] Christoph Grundner,et al. Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[15] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.
[16] S. Benichou,et al. Human Immunodeficiency Virus Type 1 Nef Incorporation into Virions Does Not Increase Infectivity , 2008, Journal of Virology.
[17] Terri Wrin,et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.
[18] R. Weiss,et al. Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. , 2012, AIDS research and human retroviruses.
[19] Loïc Martin,et al. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. , 2008, The Journal of antimicrobial chemotherapy.
[20] L. Xing,et al. Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding , 2011, Proceedings of the National Academy of Sciences.
[21] H. Revets,et al. The development of nanobodies for therapeutic applications. , 2009, Current opinion in investigational drugs.
[22] J. Sodroski,et al. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.
[23] G. Sapiro,et al. Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.
[24] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[25] J. Sodroski,et al. Species-Specific, Postentry Barriers to Primate Immunodeficiency Virus Infection , 1999, Journal of Virology.
[26] Dennis R. Burton,et al. Toward an AIDS Vaccine , 2008, Science.
[27] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[28] F. Gage,et al. In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.
[29] L. Mandelbrot,et al. The Breadth and Titer of Maternal HIV-1-Specific Heterologous Neutralizing Antibodies Are Not Associated with a Lower Rate of Mother-to-Child Transmission of HIV-1 , 2012, Journal of Virology.
[30] F. Studier,et al. Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.